Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioNTech SE ( (BNTX) ) has provided an update.
On December 18, 2025, BioNTech SE announced it had closed its acquisition of CureVac N.V., completing an exchange offer in which approximately 86.75% of CureVac’s outstanding shares were tendered, with a compulsory acquisition of the remaining shares expected in January 2026 and the subsequent delisting of CureVac. The deal is designed to strengthen BioNTech’s already significant position in the global mRNA field by adding CureVac’s technologies in mRNA design, delivery formulations and manufacturing, supporting BioNTech’s oncology strategy and consolidating two of Germany’s pioneering mRNA players under one umbrella; CureVac will initially continue operating under its existing processes while BioNTech’s leadership, now also forming CureVac’s management board, undertakes strategic and scientific analyses to define the combined group’s future organization and portfolio, with implications for a more integrated and potentially more competitive mRNA innovation platform.
The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a global next-generation immunotherapy company specializing in mRNA-based cancer immunotherapies, next-generation immunomodulators, targeted therapies such as antibody-drug conjugates and CAR-T cell therapies, as well as mRNA vaccines for infectious diseases. Leveraging deep expertise in mRNA development, in-house manufacturing, and computational discovery, BioNTech collaborates with major pharmaceutical partners including Bristol Myers Squibb, Pfizer, and others to advance a diversified pipeline across oncology and other serious diseases.
Average Trading Volume: 945,438
Technical Sentiment Signal: Sell
Current Market Cap: $22.18B
See more insights into BNTX stock on TipRanks’ Stock Analysis page.